Skip to content

Basket

You currently have no items in your basket.

Total (excl. vat) £0.00
View basket & checkout
Antibodies

Research Grade Etokimab

Product Sizes
1 mg
£506.00
DHB74001-1MG
5 mg
£1169.00
DHB74001-5MG
25 mg
£2865.00
DHB74001-25MG
About this Product
SKU:
DHB74001
Additional Names:
ANB020, CAS: 2022981-44-6,IL33
Buffer:
0.01M PBS, pH 7.4.
translate.label.attr.clone:
Etokimab
Clonality:
Recombinant Monoclonal
Concentration:
1 mg/ml
Extra Details:
ANB020, now called etokimab, is currently in phase 2a testing in eczema, which is also known as atopic dermatitis. Scientists from the Medical Research Council Human Immunology Unit at the University of Oxford released data from 12 patients showing that 83% who were treated with etokimab reported a reduction in disease severity after 29 days. Etokimab, an anti-IL-33 biologic, has previously demonstrated a good safety profile and favorable pharmacodynamic properties in many clinical studies. Etokimab is designed to block interleukin-33 (IL-33), an immune-signaling molecule. In peanut allergy, the body overreacts to peanuts as IL-33 activates an antibody called immunoglobin E. These antibodies cause allergic response such as mouth itchiness, hives, breathing difficulties and potentially fatal anaphylactic shock.
Host:
Human
Immunogen:
NF-HEV, IL-1F11, C9orf26, IL-33, Interleukin-1 family member 11, IL33, Nuclear factor from high endothelial venules, NFHEV, Interleukin-33, IL1F11
Isotype:
IgG1, kappa
Physical State:
Liquid
Purity:
>95%
Purification:
Protein A/G purified from cell culture supernatant.
Reactivities:
Human
Shipping Conditions:
Blue Ice
Source:
XtenCHO
Storage Conditions:
-20[o]C Avoid freeze/thaw cycles., 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
Supplier:
AntibodySystem
Type:
Antibody: Recombinant Antibodies